Brian K. Rhees
Corporate Officer/Principal bei Verinata Health, Inc.
Profil
Brian K.
Rhees is a professional with experience in various firms.
He is currently working as a Senior Director-Bioinformatics at Verinata Health, Inc. Previously, he worked as a Director-Biostatistics & Bioinformatics at Roche Molecular Systems, Inc. and as a Vice President-Scientific Operations at Perlegen Sciences, Inc. He completed his undergraduate degree at Brigham Young University and his doctorate at North Carolina State University.
Aktive Positionen von Brian K. Rhees
Unternehmen | Position | Beginn |
---|---|---|
Verinata Health, Inc.
Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 12.05.2010 |
Ehemalige bekannte Positionen von Brian K. Rhees
Unternehmen | Position | Ende |
---|---|---|
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA. | Corporate Officer/Principal | - |
Perlegen Sciences, Inc.
Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Brian K. Rhees
Brigham Young University | Undergraduate Degree |
North Carolina State University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Perlegen Sciences, Inc.
Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | Retail Trade |
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA. | Health Services |
Verinata Health, Inc.
Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA. | Health Services |